Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer
JournalClinical Breast Cancer
MetadataShow full item record
AbstractBackground: Progranulin (GP88) is a critical player in breast tumorigenesis. GP88 tumor expression is associated with increased recurrence and mortality, whereas GP88 circulating levels are elevated in patients with breast cancer compared with healthy individuals. We examined here the correlation between serum GP88 levels in patients with metastatic breast cancer (MBC) with overall survival and disease status determined as response to therapy or progression of disease. Patients and Methods: An institutional review board (IRB)-approved study prospectively enrolled 101 patients with MBC at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. GP88 serum levels were correlated with patients’ disease status determined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria and survival outcomes by Kaplan-Meier analysis and log rank statistics. Results: Patients’ survival was stratified by serum GP88 level. Patients with serum GP88 < 55 ng/mL had a 4-fold increased survival compared with patients with GP88 > 55 ng/mL. Examination of GP88 serum levels in association with disease status showed a statistically significant association between serum GP88 levels and disease progression or response to therapy while CA15-3 level was only associated to progression. Conclusion: The association of serum GP88 level with survival and disease status suggests the potential of using the serum GP88 test for monitoring disease status in patients with MBC. Measurement of serum GP88 levels in patients with MBC may have clinical value as a cost-effective adjunct to the management of patients with MBC with imaging. Progranulin (GP88) is a breast tumorigenesis driver. High tumor expression is associated with increased recurrence and mortality. Correlation between serum GP88 with survival and disease status was examined in 101 patients with metastatic breast cancer. Serum GP88 levels correlated with survival, therapy response, and disease progression. These data would suggest serum GP88 measurement to monitor disease status.in the standard of care. Copyright 2019 The Authors
SponsorsThis work was supported by grants R43 CA210817 , R44 CA210817 , and R44 CA162629 from the National Cancer Institute to GS.
Measurement of response to therapy
Serum GP88 enzyme immunoassay for disease monitoring
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85077716953&doi=10.1016%2fj.clbc.2019.11.010&partnerID=40&md5=278b9efc9b9b229f488d4546918e6129; http://hdl.handle.net/10713/11685